What is Triple Negative Breast Cancer? Triple Negative Breast Cancer (TNBC) is defined as a heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, and ther...
Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnostics The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas, including those outside of healthcare, such as environmental conservation. It has an annua...
Find More
FDA approves Zulresso of Sage Sage Therapeutics, a clinical-stage biopharmaceutical company committed to the treatment of central nervous system (CNS) disorders, receives U.S. approval for its postpartum depression (PPD) drug Zulresso from the Food and Drug Administration when received 17-1 in favour of the therapy...
Find More
[caption id="attachment_3536" align="aligncenter" width="1360"] Lung Cancer Infographic[/caption] Lung cancer is among the leading cause of cancer deaths with the lowest survival rate. Early detection can increase the chances of survival. As November is #LungCancerAwareness Month, we are doing our part by increasin...
Find More
It is said old is gold. True indeed! As a case in point, a 150-year-old drug has gained prominence as a potential cancer therapy in the future to bring in much relief to cancer patients. Recently, researchers from the Ohio State University in the USA have found that the drug called Papaverine could make tumours more...
Find More
Subsequent malignant neoplasms (SMNs) are one of the most serious and potentially lethal complications of cancer and its therapy. Radiotherapy has been known to be a human carcinogen, however, a growing body bolsters the selective contribution of chemotherapeutic agents to SMN risk. Cisplatin binds to and destructs ...
Find More
Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...
Find More
[caption id="attachment_3465" align="alignnone" width="800"] INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER[/caption] To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)---Market-Insight,-Epidemi...
Find More
Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...
Find More
FDA approves expanded label for Xarelto of Johnson & Johnson The Food and Drug Administration permitted labelling of blood thinner, Xarelto of Johnson & Johnson, as it can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease (CAD or P...
Find More
Spinal Cord Injury (SCI) causes extreme back pain and at times triggers an “accelerating aging” .....
Find More
Ankylosing spondylitis (AS) is an inflammatory disease that results in a progressive fusion of some .....
Find More
Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....
Find More
An inherited disorder, Von Hippel-Lindau (VHL) syndrome is characterized by the formation of tumors .....
Find More
Uremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic it.....
Find More
Cell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
